Strategy Buys $1 Billion Of Bitcoin Using Preferred Stock

CryptoProwl

Mon, April 13, 2026 astatine 7:58 AM CDT 1 min read

Serial cryptocurrency acquirer Strategy (NASDAQ: $MSTR) has purchased $1 cardinal U.S. worthy of Bitcoin (CRYPTO: $BTC) funded wholly done its preferred stock.

Strategy, led by Executive Chairman Michael Saylor, bought 13,927 Bitcoin past week, a haul worthy astir $1 cardinal U.S. based connected an mean terms of $71,902 U.S. per integer coin.

The latest acquisition is notable successful that it was wholly funded by $1 cardinal U.S. raised done income of the company’s preferred banal called Stretch (NASDAQ: $STRC).

More From Cryptoprowl:

• Ripple, The Company Behind XRP, Is Valued At $50 Billion

• Eightco Secures $125 Million Investment From Bitmine And ARK Invest, Shares Surge

• Blockchain Projects Decline 75% As Developers Shift To A.I.

• Stanley Druckenmiller Says Stablecoins Could Reshape Global Finance

• New York Stock Exchange Invests $600 Million In Polymarket

Strategy did not usage immoderate of its currency reserves to marque the latest Bitcoin purchase. 

In caller months, the institution has utilized a operation of currency connected manus and wealth raised from Stretch to money its BTC purchases. 

Stretch is simply a variable-rate preferred banal designed to supply high-yield monthly income with a unchangeable $100 U.S. worth that’s backed by the company’s Bitcoin holdings. 

Currently, Stretch pays a monthly dividend that yields 11.5%. That complaint adjusts monthly to support the stock terms adjacent $100 U.S. 

The latest play acquisition brings Strategy’s full Bitcoin holdings to 780,897, acquired for astir $59.02 cardinal U.S. astatine an mean outgo ground of $75,577 U.S.

BTC is presently trading close astir $71,000 U.S. and is down from a grounds precocious of $126,000 U.S. reached past October. 

Strategy has continued buying Bitcoin arsenic the terms has fallen and languished implicit the past six months. 

MSTR banal has fallen 59% implicit the past 12 months to commercialized astatine $128.64 U.S. per share.